Survival of guselkumab therapy in moderate to severe plaque psoriasis at 52 weeks in a real-world clinical setting: observational, retrospective, multi-centre study by the Spanish Psoriasis Group

Colaboración

Año: 2022

del Alcazar, E; Lopez-Ferrer, A; Martinez-Domenech, A; Julia, M; Ruiz-Villaverde, R; Fernandez-Freire, LR; Notario, J; Llamas-Velasco, M; Ferran, M; Carrascosa, JM

Título: JOURNAL OF DERMATOLOGICAL TREATMENT

• Q2